Company Filing History:
2 out of 34 
2 out of 2 Years Active: 2023-2025
Title: Rebekka Duhen: Innovator in Cancer Treatment
Introduction
Rebekka Duhen is a prominent inventor based in Portland, Oregon. She has made significant contributions to the field of cancer treatment through her innovative research and patented methods. With a total of two patents, her work focuses on the identification and treatment of human tumor-reactive T cells.
Latest Patents
Duhen's latest patents include methods for utilizing CD39 and CD103 for the identification of human tumor-reactive T cells for cancer treatment. These methods involve administering a therapeutically effective amount of CD8CD39CD103 T cells to subjects with tumors. Additionally, her patents disclose techniques for isolating nucleic acids encoding T cell receptors (TCRs) that specifically bind to tumor cell antigens. This includes isolating CD8CD39CD103 T cells from tumor samples and cloning the nucleic acid molecules encoding TCRs. Furthermore, her methods provide ways to expand CD8CD39CD103 T cells and determine if a subject will respond to checkpoint inhibitors by detecting the presence of these T cells in biological samples.
Career Highlights
Throughout her career, Duhen has worked with notable organizations such as Providence Health & Services and Agonox, Inc. Her experience in these companies has allowed her to advance her research and contribute to the development of innovative cancer therapies.
Collaborations
Duhen has collaborated with esteemed colleagues, including Andrew D. Weinberg and Thomas Duhen. These partnerships have further enriched her research and expanded the impact of her work in the field of oncology.
Conclusion
Rebekka Duhen is a trailblazer in the realm of cancer treatment, with her innovative patents paving the way for new therapeutic approaches. Her dedication to advancing medical science continues to inspire and influence the field.